文献速递头颈与中枢神经肿瘤

头颈部肿瘤机会窗试验的视角:EORTC 90111-24111-NOCI-HNCG 研究的经验

Perspectives on window of opportunity trials in head and neck cancer: lessons from the EORTC 90111-24111-NOCI-HNCG study.
PubMed 文献 · Eur J Cancer · 2018-10-06

传统 I–III 期试验评估肿瘤反应存在局限,机会窗试验(术前给药、不同于新辅助)试图克服这些局限。EORTC 90111-24111-NOCI-HNCG 研究在初治头颈部鳞癌中评估阿法替尼,首次证实其活性并定义潜在预测生物标志物,同时揭示患者选择、肿瘤部位及组织管理等挑战。本报告详述该研究的关键经验并为克服机会窗试验设计挑战提供建议。

要点

  • 机会窗试验可术前评估靶向药物活性,但面临患者选择与肿瘤部位等挑战。
  • EORTC 90111-24111-NOCI-HNCG 研究首次证实阿法替尼在初治头颈部鳞癌中的活性。
  • 该研究定义了阿法替尼的潜在预测生物标志物。

核心结论

  • 机会窗试验设计可评估靶向治疗活性并定义预测生物标志物,但需克服患者选择、肿瘤部位及组织管理等多重挑战。

研究设计与样本

  • 本报告基于 EORTC 90111-24111-NOCI-HNCG 机会窗试验,该试验在初治头颈部鳞癌患者中评估阿法替尼。

主要发现

  • 该研究首次证实阿法替尼在初治头颈部鳞癌中具有活性,并定义了其潜在预测生物标志物。
  • 研究揭示了机会窗试验设计相关的挑战,包括患者选择、肿瘤部位及其他组织管理问题的影响。

临床怎么用

  • 本报告为肿瘤内科医生提供机会窗试验设计的经验与建议,以优化未来靶向药物术前评估。

局限性

  • 机会窗试验设计面临患者选择、肿瘤部位及组织管理等多方面挑战,可能影响试验实施与结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Assessing tumour response using a traditional phase I, II and III trial approach is not without limitations, particularly when targeted therapies are involved. Window of opportunity trials, performed presurgically but differing from neoadjuvant studies, were developed in an attempt to overcome the limitations of the traditional approach. A recent window of opportunity trial, the EORTC 90111-24111-NOCI-HNCG study, evaluated afatinib in treatment-naive patients with squamous cell carcinoma of the head and neck. While this study was the first to demonstrate the activity of afatinib in this setting and to define its potential predictive biomarkers, it also highlighted the challenges associated with the window of opportunity trial design, including the impact of patient selection, tumour site, and other organisational issues. This report details the key learnings from the EORTC 90111-24111-NOCI-HNCG study and provides recommendations to overcome the challenges of this particular trial design.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schmitz S, Caballero C, Locati LD, et al. Perspectives on window of opportunity trials in head and neck cancer: lessons from the EORTC 90111-24111-NOCI-HNCG study. Eur J Cancer. 2018. PMID: 30301582. doi:10.1016/j.ejca.2018.07.315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。